Evidence map›Paper›PMID 19998480›Full record

ArticleGlia2010

Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia.

Niranjan B Butchi, Min Du, Karin E Peterson

Abstract read
In one paragraph

Article in Glia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Niranjan B ButchiLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, MT 59840, USA.
Min Du
Karin E Peterson
National Institute of Allergy and Infectious Diseases · US

Funding

TNF AND MCP-1 IN RETROVIRUS-INDUCED BRAIN DISEASEP20RR020159 · NCRR · LOUISIANA STATE UNIV A&M COL BATON ROUGE · PI PAHAR, BAPI · 2004 to 2011
$16.1M
Regulation of Innate Immune Responses in the Central Nervous SystemZIAAI001101 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PETERSON, KARIN · 2009 to 2015
$2.6M
Intramural NIH HHS ZIA AI001101NCIRD CDC HHS IP20RR020159NCRR NIH HHS P20 RR020159
6 · The paper itself

Abstract

Toll-like receptors 7 (TLR7) and 9 (TLR9) are important mediators of innate immune responses. Both receptors are located in endosomal compartments, recognize nucleic acids, and signal via Myeloid differentiation factor 88 (MyD88). In the current study, we analyzed TLR7 and TLR9 induced activation of astrocytes and microglia, two cell types that contribute to innate immune responses in the CNS. TLR7 and TLR9 agonists induced similar cytokine profiles within each cell type. However, there were notable differences in the cytokine profile between astrocytes and microglia, including the production of the anti-inflammatory cytokine IL-10 and antiapoptotic cytokines G-CSF and IL-9 by microglia but not astrocytes. Costimulation studies demonstrated that the TLR7 agonist, imiquimod, could inhibit TLR9 agonist-induced innate immune responses, in both cell types, in a concentration-dependent manner. Surprisingly, this inhibition was not mediated by TLR7, as deficiency in TLR7 did not alter suppression of the TLR9 agonist-induced responses. The suppression of innate immune responses was also not due to an inhibition of TLR9 agonist uptake. This suggested that imiquimod suppression may be a direct effect, possibly by blocking CpG-ODN binding and/or signaling with TLR9, thus limiting cell activation. An antagonistic relationship was also observed between the two receptors in microglia, with TLR7 deficiency resulting in enhanced cytokine responses to CpG-ODN stimulation. Thus, both TLR7 and its agonist can have inhibitory effects on TLR9-induced cytokine responses in glial cells.

Indexed as

Adjuvants, ImmunologicAminoquinolinesAnalysis of VarianceAnimalsApoptosisAstrocytesCells, CulturedCerebral CortexCytokinesDose-Response Relationship, DrugEmbryo, MammalianFlow CytometryGene Expression RegulationImiquimodMembrane GlycoproteinsMiceAdjuvants, ImmunologicAminoquinolinesCPG-oligonucleotideCytokinesImiquimodMembrane GlycoproteinsNerve Tissue ProteinsOligodeoxyribonucleotidesRNA, MessengerTlr7 protein, mouseTlr9 protein, mouseToll-Like Receptor 7Toll-Like Receptor 9

Identifiers

PMID19998480
PMCPMC3767435
OpenAlexW1970216950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.